Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
Meredith Cook, SR. VP, GENERAL COUNSEL & SEC. of ANI Pharmaceuticals Inc (NASDAQ:ANIP), sold 400 shares of common stock on August 13, 2025, at a price of $88.87, for a total transaction value of $35548.
Following the transaction, Cook directly owns 76474 shares of ANI Pharmaceuticals. The sale was executed under a Rule 10b5-1 trading plan adopted on September 17, 2024. According to InvestingPro analysis, the stock’s technical indicators suggest overbought conditions, with the company now valued at $1.81 billion. For deeper insights into insider trading patterns and 15+ additional ProTips, consider exploring the comprehensive Pro Research Report available on InvestingPro.
In other recent news, ANI Pharmaceuticals reported strong financial results for the second quarter of 2025, surpassing market expectations. The company achieved an adjusted non-GAAP earnings per share (EPS) of $1.80, exceeding FactSet consensus estimates of $1.41, and reported revenue of $211.4 million, which was above the forecast of $187.34 million. This performance was largely driven by the Cortrophin Gel product line, which saw revenue reach $81.6 million, marking a 66% year-over-year growth and a 54% sequential increase from the first quarter of 2025. Following these results, ANI Pharmaceuticals raised its guidance for revenue, adjusted EBITDA, and EPS.
Analyst firms have responded positively to these developments. Truist Securities increased its price target for ANI Pharmaceuticals to $77 from $65, maintaining a Hold rating. H.C. Wainwright also raised its price target to $93 from $84, while maintaining a Buy rating. These upgrades reflect the strong performance of the company’s product lines and its revised financial outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.